TY - JOUR T1 - Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators. AU - Girard,P M, AU - Guiguet,M, AU - Bollens,D, AU - Goderel,I, AU - Meyohas,M C, AU - Lecomte,I, AU - Raguin,G, AU - Frottier,J, AU - Rozenbaum,W, AU - Jaillon,P, Y1 - 2000/10/25/ PY - 1999/11/29/received PY - 2000/03/22/revised PY - 2000/10/26/pubmed PY - 2001/3/3/medline PY - 2000/10/26/entrez SP - 987 EP - 94 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 31 IS - 4 N2 - We designed a cohort in order to assess the long-term effects of triple-drug antiretroviral combinations in 608 patients infected with human immunodeficiency virus type 1 (HIV-1). We recruited patients who had been previously treated with nucleoside analogues as well as treatment-naive patients who were starting triple-drug antiretroviral combinations consisting of nucleoside analogues, either alone or in combination with a protease inhibitor. After a median follow-up time of 22 months, the incidence rates of acquired immune deficiency syndrome-defining events and death were, respectively, 6.9 (95% confidence interval [CI], 5.3-8.8) and 2.9 (95% CI, 1.9-4.2) per 100 person-years. Advanced clinical stage of disease (P=.004), a low CD4(+) cell count (P=.002), and a low quality-of-life score (P=.001) at baseline were independent predictors of clinical progression. The initial triple-drug combination was modified a total of 647 times in 321 patients. The only independent predictor of treatment modification was previous exposure to a nucleoside analogue in patients who did not receive a new nucleoside analogue at inclusion (P=.001). Plasma HIV RNA values below 500 copies/mL were obtained in 88% of the treatment-naive patients and in 57% of the previously treated patients (P<.001). Compared with previously treated patients who received > or = 1 new nucleoside analogue at enrollment, previously treated patients who did not receive a new nucleoside analogue at enrollment were twice as likely to have plasma HIV RNA values >500 copies/mL at the last visit (adjusted odds ratio [OR], 1.8; 95% confidence interval [CI], 1.2-2.8), and the antiretroviral-naive patients were significantly less likely to have plasma HIV RNA values >500 copies/mL at the last visit (adjusted OR, 0.2; 95% CI, 0.1-0.4). SN - 1058-4838 UR - https://www.unboundmedicine.com/medline/citation/11049781/Long_term_outcome_and_treatment_modifications_in_a_prospective_cohort_of_human_immunodeficiency_virus_type_1_infected_patients_on_triple_drug_antiretroviral_regimens__Triest_Cohort_Investigators_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/318154 DB - PRIME DP - Unbound Medicine ER -